Erasca, Inc.(ERAS)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Erasca remains a pre-revenue clinical-stage entity characterized by significant R&D intensity and a rapidly depleting cash position.
• The firm's reliance on external financing to sustain quarterly operating losses, which reached $37.9 million in 2026Q1, creates substantial dilution risk for shareholders.
• Investors should monitor the company's ability to achieve clinical milestones before the current $47.3 million cash balance necessitates further capital raises.